RT Journal Article
T1 A geroscience approach for Parkinson's disease: Conceptual framework and design of PROPAG-AGEING project.
A1 Pirazzini, Chiara
A1 Azevedo, Tiago
A1 Baldelli, Luca
A1 Bartoletti-Stella, Anna
A1 Calandra-Buonaura, Giovanna
A1 Dal Molin, Alessandra
A1 Dimitri, Giovanna Maria
A1 Doykov, Ivan
A1 Gómez-Garre, Pilar
A1 Hägg, Sara
A1 Hällqvist, Jenny
A1 Halsband, Claire
A1 Heywood, Wendy
A1 Jesús, Silvia
A1 Jylhävä, Juulia
A1 Kwiatkowska, Katarzyna Malgorzata
A1 Labrador-Espinosa, Miguel A
A1 Licari, Cristina
A1 Maturo, Maria Giovanna
A1 Mengozzi, Giacomo
A1 Meoni, Gaia
A1 Milazzo, Maddalena
A1 Periñán-Tocino, Maria Teresa
A1 Ravaioli, Francesco
A1 Sala, Claudia
A1 Sambati, Luisa
A1 Schade, Sebastian
A1 Schreglmann, Sebastian
A1 Spasov, Simeon
A1 Tenori, Leonardo
A1 Williams, Dylan
A1 Xumerle, Luciano
A1 Zago, Elisa
A1 Bhatia, Kailash P
A1 Capellari, Sabina
A1 Cortelli, Pietro
A1 Garagnani, Paolo
A1 Houlden, Henry
A1 Liò, Pietro
A1 Luchinat, Claudio
A1 Delledonne, Massimo
A1 Mills, Kevin
A1 Mir, Pablo
A1 Mollenhauer, Brit
A1 Nardini, Christine
A1 Pedersen, Nancy L
A1 Provini, Federica
A1 Strom, Stephen
A1 Trenkwalder, Claudia
A1 Turano, Paola
A1 Bacalini, Maria Giulia
A1 Franceschi, Claudio
A1 PROPAG-AGEING Consortium, 
K1 Inflammaging
K1 Neurodegeneration
K1 Omics
K1 Parkinson's disease
AB Advanced age is the major risk factor for idiopathic Parkinson's disease (PD), but to date the biological relationship between PD and ageing remains elusive. Here we describe the rationale and the design of the H2020 funded project "PROPAG-AGEING", whose aim is to characterize the contribution of the ageing process to PD development. We summarize current evidences that support the existence of a continuum between ageing and PD and justify the use of a Geroscience approach to study PD. We focus in particular on the role of inflammaging, the chronic, low-grade inflammation characteristic of elderly physiology, which can propagate and transmit both locally and systemically. We then describe PROPAG-AGEING design, which is based on the multi-omic characterization of peripheral samples from clinically characterized drug-naïve and advanced PD, PD discordant twins, healthy controls and "super-controls", i.e. centenarians, who never showed clinical signs of motor disability, and their offspring. Omic results are then validated in a large number of samples, including in vitro models of dopaminergic neurons and healthy siblings of PD patients, who are at higher risk of developing PD, with the final aim of identifying the molecular perturbations that can deviate the trajectories of healthy ageing towards PD development.
YR 2020
FD 2020-12-29
LK http://hdl.handle.net/10668/16887
UL http://hdl.handle.net/10668/16887
LA en
DS RISalud
RD Apr 9, 2025